Emergent BioSolutions cuts full-year 2026 revenue and EBITDA guidance
In a September 14 investor presentation, the company lowered its 2026 financial outlook and set third-quarter revenue guidance of $110 million to $130 million.
SEC filing
Latest
2 stories
Monday, September 14
Wednesday, August 5
Emergent BioSolutions posts Q2 revenue surge but takes $191 million impairment, cuts 2026 outlook
The company reported 66% revenue growth on government biodefense contracts while announcing a restructuring plan and slashing its full-year revenue forecast by up to $85 million.
SEC filing